Abstract
The current antithrombotic therapy recommendation for patients on oral anticoagulation who undergo coronary stenting consists of a triple therapy with aspirin, clopidogrel and a vitamin K antagonist. As the data on triple therapy derives mainly from observational studies and only one randomized trial, the level of evidence is low however. This review reflects recent developments in the setting of triple therapy including choice of (i) newer P2Y12 blocker (prasugrel, ticagrelor), (II) new oral anticoagulants (dabigatran, rivaroxaban, apixaban), (iii) drug eluting vs. bare metal stents and (iv) use of aspirin.
